Description

Carmona-Bayonas et al developed the Clinical Index of Stable Febrile Neutropenia (CISNE) to evaluate patients with stable neutropenia following chemotherapy for solid tumors. This can help to identify a patient who is at increased risk for serious complications. The authors are from multiple institutions in Spain and Chile.


 

Patient selection: adult with febrile neutropenia after chemotherapy of mild to moderate intensity, clinically stable

 

Febrile neutropenia: fever >= 38°C, absolute neutrophil count <= 500 per µL (or <= 1,000 per µL but expected to be <= 500 per µL)

 

Time period for stability: first 3 hours after onset of febrile neutropenia

 

Status: no evidence of organ failure, no sepsis or septic shock, no known severe infections, no other serious complications

 

Outcomes: shock, organ failure, death

 

Parameters:

(1) ECOG performance status

(2) stress-induced hyperglycemia

(3) COPD

(4) chronic cardiovascular disease

(5) mucositis

(6) absolute monocyte count

 

Parameter

Finding

Points

ECOG performance status

0 or 1

0

 

2, 3 or 4

2

stress-induced hyperglycemia

no

0

 

yes

2

COPD

no

0

 

yes

1

chronic cardiovascular disease

no

0

 

yes

1

mucositis

none or Grade 1

0

 

Grade 2, 3 or 4

1

absolute monocyte count

>= 200 per microliter

0

 

< 200 per microliter

1

 

total score =

= SUM(points for all 6 parameters)

 

Interpretation:

• minimum score: 0

• maximum score: 8

• The higher the score the greater the risk of serious complications.

 

Total Score

Risk

0

low

1 or 2

intermediate

3 to 8

high

 

Performance:

• The score was validated at multiple cancer centers.

 


To read more or access our algorithms and calculators, please log in or register.